Innovent Biologics Inc logo

1801 - Innovent Biologics Inc Share Price

HK$62.4 -0.4  -0.6%

Last Trade - 9:08am

Sector
Healthcare
Size
Large Cap
Market Cap £8.71bn
Enterprise Value £8.11bn
Revenue £192.9m
Position in Universe 126th / 5933
Bullish
Bearish
Unlock 1801 Revenue
Momentum
Relative Strength (%)
1m +3.85%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -9.96%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 18.5 9.48 1,048 2,867 4,389
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, InnoventBiologics Inc revenues increased from RMB345.5M toRMB984.2M. Net loss decreased 15% to RMB608.2M. Revenuesreflect People's Republic of China segment increase fromRMB345.5M to RMB948.9M. Lower net loss reflects Other gainsand losses decrease from RMB9.8M (expense) to RMB97.5M(income), Other income increase of 92% to RMB107.4M(income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for 1801
Graphical History

Revenue

1801 Revenue Unlock 1801 Revenue

Net Income

1801 Net Income Unlock 1801 Revenue

Normalised EPS

1801 Normalised EPS Unlock 1801 Revenue

PE Ratio Range

1801 PE Ratio Range Unlock 1801 Revenue

Dividend Yield Range

1801 Dividend Yield Range Unlock 1801 Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
1801 EPS Forecasts Unlock 1801 Revenue
Profile Summary

Innovent Biologics, Inc. is a China-based biopharmaceutical company. The Company’s main products include PD-1 antibody; bevacizumab (Avastin) biosimilar, IBI-305; rituximab (MabThera/Rituxan) biosimilar, IBI-301; and adalimumab (Humira) biosimilar, IBI-303.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated April 28, 2011
Public Since October 31, 2018
No. of Shareholders: n/a
No. of Employees: 1,100
Sector Healthcare
Industry Pharmaceuticals
Index Hang Seng Composite , Hang Seng Composite LargeCap & MidCap , Hang Seng Mainland 100 , Hang Seng Composite MidCap , Hang Seng Composite Mid & SmallCap ,
Exchange Stock Exchange of Hong Kong Limited
Shares in Issue 1,400,058,997
Free Float (0.0%)
Eligible for
ISAs
SIPPs
1801 Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for 1801
Upcoming Events for 1801
Frequently Asked Questions for Innovent Biologics Inc
What is the Innovent Biologics Inc share price?

As of 9:08am, shares in Innovent Biologics Inc are trading at HK$62.4, giving the company a market capitalisation of £8.71bn. This share price information is delayed by 15 minutes.

How has the Innovent Biologics Inc share price performed this year?

Shares in Innovent Biologics Inc are currently trading at HK$62.4 and the price has moved by 0.166k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Innovent Biologics Inc price has moved by 0.165k% over the past year.

What are the analyst and broker recommendations for Innovent Biologics Inc?

Of the analysts with advisory recommendations for Innovent Biologics Inc, there are there are currently 6 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Innovent Biologics Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Innovent Biologics Inc next release its financial results?

Innovent Biologics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Innovent Biologics Inc dividend yield?

Innovent Biologics Inc does not currently pay a dividend.

Does Innovent Biologics Inc pay a dividend?

Innovent Biologics Inc does not currently pay a dividend.

When does Innovent Biologics Inc next pay dividends?

Innovent Biologics Inc does not currently pay a dividend.

How do I buy Innovent Biologics Inc shares?

To buy shares in Innovent Biologics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Innovent Biologics Inc?

Shares in Innovent Biologics Inc are currently trading at HK$62.4, giving the company a market capitalisation of £8.71bn.

Where are Innovent Biologics Inc shares listed? Where are Innovent Biologics Inc shares listed?

Here are the trading details for Innovent Biologics Inc:

Country of listing: Hong Kong
Exchange: HKG
Ticker Symbol: 1801
What kind of share is Innovent Biologics Inc?

Based on an overall assessment of its quality, value and momentum, Innovent Biologics Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Innovent Biologics Inc share price forecast 2020?

Shares in Innovent Biologics Inc are currently priced at HK$62.4. At that level they are trading at 9.08% premium to the analyst consensus target price of 0.00.

Analysts covering Innovent Biologics Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.5728801512 for the next financial year.

How can I tell whether the Innovent Biologics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Innovent Biologics Inc. Over the past six months, the relative strength of its shares against the market has been 37.73%. At the current price of HK$62.4, shares in Innovent Biologics Inc are trading at 40.9% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Innovent Biologics Inc PE Ratio?

We were not able to find PE ratio data for Innovent Biologics Inc.

Who are the key directors of Innovent Biologics Inc?

Innovent Biologics Inc's management team is headed by:

De-Chao Yu - CHM
Hao Xi Ede - CFO
Shuyun Chen - NED
Charles Cooney - NID
I-Yin Hsu - NID
Kaixian Chen - NID
Qinwei Zhou - COO
Yanju Wang - SEC
Lok Yee Chan - SEC
Who are the major shareholders of Innovent Biologics Inc?

Here are the top five shareholders of Innovent Biologics Inc based on the size of their shareholding:

Temasek Holdings Pte. Ltd. Sovereign Wealth Fund
Percentage owned: 7.89% (110.5m shares)
Yu (De-Chao Michael) Individual Investor
Percentage owned: 7.58% (106.1m shares)
Lilly Asia Ventures Venture Capital
Percentage owned: 4.27% (59.7m shares)
Invesco Advisers, Inc. Investment Advisor
Percentage owned: 4.09% (57.2m shares)
Capital International, Inc. Investment Advisor
Percentage owned: 3.61% (50.5m shares)
Similar to 1801
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.